James R. Jett

James R. Jett's AcademicInfluence.com Rankings

James R. Jett

Medical

#2915

World Rank

#3359

Historical Rank

Oncology

#196

World Rank

#202

Historical Rank

medical Degrees

Download Badge

Medical

Why Is James R. Jett Influential?

(Suggest an Edit or Addition)

(See a Problem?)

James R. Jett's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. (2005) (1192)
Benefits and harms of CT screening for lung cancer: a systematic review. (2012) (1076)
Screening for lung cancer with low-dose spiral computed tomography. (2000) (691)
Lung cancer screening with CT: Mayo Clinic experience. (2003) (664)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. (2011) (600)
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. (2008) (544)
CT screening for lung cancer: five-year prospective experience. (2005) (539)
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. (2012) (535)
Primary mediastinal tumors: part II. Tumors of the middle and posterior mediastinum. (1997) (473)
Computed tomography screening and lung cancer outcomes. (2007) (463)
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. (2009) (458)
Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum. (1997) (399)
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. (2005) (392)
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer (2007) (325)
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. (2013) (289)
Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. (2013) (278)
Non-small-cell lung cancer (2011) (268)
Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. (2004) (262)
The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer (2008) (262)
A new immunodeficiency disorder in humans involving NK cells (1980) (260)
Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. (2007) (227)
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. (2003) (218)
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. (2000) (205)
A Five-Year Experience (2017) (202)
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. (1999) (198)
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. (2001) (197)
The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (197)
Profiling Tumor-Associated Antibodies for Early Detection of Non-small Cell Lung Cancer (2006) (196)
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. (1991) (188)
Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement. (2001) (186)
Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement. (2015) (169)
Superior pulmonary sulcus tumors and Pancoast's syndrome. (1997) (166)
Erdheim-Chester disease: clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease. (1999) (155)
Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. (2004) (154)
The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification (2016) (152)
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. (2005) (150)
Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. (1995) (145)
Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). (2007) (142)
Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. (1996) (140)
Pulmonary resection of metastatic renal cell carcinoma. (1983) (137)
Does interstitial lung disease predispose to lung cancer? (2005) (136)
Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases (1986) (135)
Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). (2007) (130)
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. (2005) (129)
Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. (1996) (126)
Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening (2005) (124)
Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. (2004) (121)
Prognostic factors differ by tumor stage for small cell lung cancer (2009) (116)
The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. (2007) (116)
Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. (1994) (115)
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. (2000) (113)
Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. (2005) (113)
Phospho-Akt Overexpression in Non–Small Cell Lung Cancer Confers Significant Stage-Independent Survival Disadvantage (2004) (112)
A prognostic model for advanced stage nonsmall cell lung cancer (2006) (112)
Pulmonary resection of metastatic colorectal adenocarcinoma. A ten year experience. (1986) (109)
Advances in chemotherapy of non-small cell lung cancer. (2006) (109)
Augmentation of human monocyte-mediated cytolysis by interferon. (1980) (108)
Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. (1994) (107)
Effectiveness of smoking cessation self-help materials in a lung cancer screening population. (2004) (106)
Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. (2014) (105)
The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. (1994) (103)
Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. (2012) (103)
Change in smoking status after spiral chest computed tomography scan screening (2003) (102)
Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. (2007) (102)
Tumor response and progression‐free survival as potential surrogate endpoints for overall survival in extensive stage small‐cell lung cancer (2011) (97)
Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. (2010) (95)
Approach to the solitary pulmonary nodule. (1993) (95)
Leukoencephalopathy in Small Cell Lung Cancer Patients Receiving Prophylactic Cranial Irradiation (1989) (93)
Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer (2007) (92)
Using protein microarray as a diagnostic assay for non-small cell lung cancer. (2005) (92)
A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. (2010) (91)
An integrated approach to evaluation of the solitary pulmonary nodule. (1990) (90)
Limitations of Screening for Lung Cancer with Low-Dose Spiral Computed Tomography (2005) (89)
The correlation of emphysema or airway obstruction with the risk of lung cancer: a matched case-controlled study (2002) (88)
Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. (2002) (88)
5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size. (2009) (84)
Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007 (2008) (84)
Clinical Respiratory Medicine (2004) (84)
Guidelines on treatment of stage IIIB non-small cell lung cancer. (2003) (82)
The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (81)
Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. (2005) (74)
A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials (2007) (71)
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. (2006) (70)
Thoracic surgical operations in patients enrolled in a computed tomographic screening trial. (2004) (70)
Results of combined‐modality therapy for limited‐stage small cell lung carcinoma in the elderly (2005) (69)
A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. (2006) (68)
The value of bronchoscopy in the diagnosis of mycobacterial disease. A five-year experience. (1981) (67)
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. (2005) (66)
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). (2008) (65)
Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. (1994) (64)
Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. (1994) (63)
Added Value of a Serum Proteomic Signature in the Diagnostic Evaluation of Lung Nodules (2012) (62)
Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. (2005) (59)
Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. (1999) (57)
O-127 Evaluation of nodules detected by screening for lung cancer with low dose spiral computed tomography (2003) (56)
Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. (1990) (55)
Screening for lung cancer: current status and future directions: Thomas A. Neff lecture. (2004) (54)
Current treatment of unresectable lung cancer. (1993) (52)
The value of combined‐modality therapy in elderly patients with stage III nonsmall cell lung cancer (2007) (51)
Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. (2001) (49)
Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis. (2004) (48)
Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. (2008) (48)
Clinical strategies for solitary pulmonary nodule. (1992) (48)
Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. (2002) (47)
p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. (1998) (47)
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. (2009) (47)
Acquired immunodeficiency syndrome associated with blood-product transfusions. (1983) (47)
S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC) (2008) (46)
Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer (2007) (45)
Comprehensive Respiratory Medicine (1999) (45)
Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung. (1993) (44)
A prospective study of pulmonary function in patients receiving mitomycin. (1996) (44)
MicroRNA and mRNA Features of Malignant Pleural Mesothelioma and Benign Asbestos-Related Pleural Effusion (2015) (43)
Imatinib mesylate-induced interstitial pneumonitis. (2003) (43)
Comparison of Programmed Death Ligand‐1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens (2018) (42)
Benzo(A)pyrene metabolism and blast transformation in peripheral blood mononuclear cells from smoking and nonsmoking populations and lung cancer patients (1978) (42)
Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. (1998) (42)
Polymorphisms in the promoter region of the neutrophil elastase gene are associated with lung cancer development. (2002) (41)
A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) (2005) (41)
Cannabis Use, Lung Cancer, and Related Issues (2018) (41)
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers (2011) (40)
Spiral computed tomography screening for lung cancer is ready for prime time. (2001) (39)
Scientific Advances in Thoracic Oncology 2016. (2017) (39)
Lung cancer: Current concepts and prospects (1983) (39)
Results of combination chemotherapy and thoracic radiation therapy for unresectable non-small cell carcinoma of the lung. (1989) (39)
Plastic bronchitis: an old disease revisited. (1991) (38)
p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. (1998) (38)
A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study (2007) (38)
Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study (2012) (36)
Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium (2015) (36)
Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. (2000) (33)
A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients (2004) (32)
Phase II trial of topotecan for the treatment of mesothelioma. (1998) (32)
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. (2000) (32)
Extent of Resection and Lymph Node Assessment for Clinical Stage T1aN0M0 Typical Carcinoid Tumors. (2018) (32)
18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma * (2009) (31)
Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules (2018) (30)
A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma (1992) (30)
Variation of microsomal mixed function oxidase(s) and human lung cancer (1980) (29)
Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. (2014) (29)
An Official American Thoracic Society Research Statement: A Research Framework for Pulmonary Nodule Evaluation and Management. (2015) (29)
Glomus tumor of the trachea: value of multidetector computed tomographic virtual bronchoscopy. (2004) (28)
Weekly Carboplatin and Paclitaxel in Elderly Non–Small-Cell Lung Cancer Patients (≥65 Years of Age): A Phase II North Central Cancer Treatment Group Study (2003) (28)
p53 mutations and occupational exposures in a surgical series of lung cancers. (1996) (28)
Fluorescence in situ hybridization testing algorithm improves lung cancer detection in bronchial brushing specimens. (2010) (28)
Postoperative adjuvant treatments for non-small cell lung cancers: a consensus report (1991) (28)
Small cell lung cancer: current therapy and promising new regimens. (2002) (28)
Screening for Lung Cancer: For Patients at Increased Risk for Lung Cancer, It Works (2011) (27)
Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive‐stage small cell lung carcinoma (2003) (26)
D7-07: A phase II NCCTG “Window of Opportunity Front-line” study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC (2007) (25)
38 Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy (1997) (25)
Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease. (1996) (25)
Como international conference position statement: lung cancer screening for early diagnosis 5 years after the 1998 Varese conference. (2005) (24)
Pathologic review of the Mayo Lung Project (2002) (23)
Superior sulcus tumors and Pancoast's syndrome. (2003) (22)
Do patients with schizophrenia receive state‐of‐the‐art lung cancer therapy? A brief report (2008) (22)
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. (1986) (22)
Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. (2012) (22)
Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients (2003) (21)
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies (2013) (21)
Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer (2015) (21)
A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. (1995) (20)
Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer. (1999) (20)
Computed tomographic screening for lung cancer: home run or foul ball? (2003) (20)
Screening for lung cancer: The US studies (2013) (20)
Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer (2010) (20)
Screening for lung cancer in high-risk groups: current status of low-dose spiral CT scanning and sputum markers. (2000) (19)
Screening for non-small cell lung cancer. (2005) (19)
Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer Patients after Initial Treatment with Platinum-Based Chemotherapy: An NCCTG-97-24-51 Based Study (2009) (19)
Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma. (1985) (18)
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer (2018) (18)
Progress in the development of volatile exhaled breath signatures of lung cancer. (2015) (18)
Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment group. (1990) (18)
Expert opinion: role of percutaneous biopsy of part-solid nodules in the IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma. (2011) (18)
A Phase I‐II Study of Sequential Infusion VP‐16 and Cisplatin Therapy in Advanced Lung Cancer (1989) (18)
Staging classification committee. (1997) (18)
Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trial. (1999) (18)
Commentary: CT screening for lung cancer--caveat emptor. (2008) (18)
A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1). (2002) (18)
What's new in staging of lung cancer? (1997) (17)
242 Promising long term outcome of weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC) (1997) (17)
New agents in the treatment of small cell lung cancer. (1998) (17)
Development of multifield three-dimensional conformal radiotherapy of lung cancer using a total lung dose/volume histogram (1995) (16)
Measurable or assessable disease in lung cancer trials: does it matter? (1994) (16)
Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials (2006) (16)
Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma. (1993) (16)
A randomized phase II trial of amonafide or trimetrexate in patients with advanced non‐small cell lung cancer. A trial of the north central cancer treatment group (1993) (16)
Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer. (1996) (16)
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. (2004) (15)
Treatment toxicities in long-term survivors of limited small cell lung cancer. (1988) (15)
A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancer. (1988) (15)
Road ahead to respiratory health: Experts chart future research directions (2009) (15)
Randomized phase II trial of sulindac for lung cancer chemoprevention. (2013) (15)
In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin (2004) (15)
Updates Regarding Biomarker Testing for Non–Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable (2019) (15)
Differing Response Rates and Survival Between Squamous and Non‐Squamous Non‐Small Cell Lung Cancer Comparison of CAP Versus MAP (1986) (14)
Inhibitory effect of murine recombinant interferon (beta) on the pulmonary metastasis of B-16 melanoma. (1986) (14)
Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies (2018) (14)
Aryl hydrocarbon hydroxylase in man and lung cancer. (1978) (14)
Non-Hodgkin's lymphoma presenting as Pancoast's syndrome. (1997) (13)
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer. (1985) (13)
Long‐Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance) (2017) (13)
Preoperative evaluation of pulmonary risk factors (1988) (13)
Phase II trial of edatrexate in small cell lung cancer (1994) (12)
Targeted therapy for non-small cell lung cancer. (2013) (12)
Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules. (2004) (11)
Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution. (2005) (11)
Flow cytometric enrichment for respiratory epithelial cells in sputum (2004) (11)
O-161 Screening for lung cancer with low dose spiral computed tomography (SCT): The Mayo clinic trial (2003) (11)
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. (2007) (11)
Colony Inhibitory Effect of Recombinant Human Tumor Necrosis Factor (rH-TNF) and/or Recombinant Human Interferon (rH-IFN)-α -β and -γ on Human Lung Cancer Cell Lines (1987) (11)
Universal detection of aerodigestive cancers by assay of nonapoptotic human DNA in stool (2000) (11)
Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis (2010) (11)
Assessment of Integrated Classifier's Ability to Distinguish Benign From Malignant Lung Nodules: Extended Analyses and 2 Year Follow-Up Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. (2020) (11)
Update in lung cancer 2005. (2006) (11)
A phase II NCCTG/CALGB trial of imatinib (STI571) in patients (pts) with c-kit-expressing relapsed small cell lung cancer (SCLC) (2005) (10)
Considerations in optimizing radiation therapy for non-small cell lung cancer. (1998) (10)
Is there a role for interferon in the treatment of small cell lung cancer (1989) (9)
State of the journal: 2011. (2011) (9)
Macromolecular binding of 3H-benzo(a)pyrene metabolites and lymphocyte transformation in patients with lung cancer, and in smoking and nonsmoking control subjects. (1979) (9)
Update on screening for lung cancer. (2008) (9)
Chemotherapy for malignant mesothelioma: CAMEO (1982) (9)
Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer: A North Central Cancer Treatment Group Study (2010) (8)
Fatal Radiation Pneumonitis in Patients With Subclinical Interstitial Lung Disease (2018) (8)
Phase II trial of topotecan and paclitaxel (TP) with G-CSF support alternating with etoposide and cisplatin (EC) in previously untreated extensive stage small cell lung cancer (ED-SCLC): A North Central Cancer Treatment Group study (2000) (8)
Alternating Chemotherapy With or Without VP‐16 in Extensive‐Stage Small‐Cell Lung Cancer (1989) (8)
The New Official Journal of the IASLC (2006) (8)
Change in smoking status after low-dose spiral chest CT screening for lung cancer: opportunity for smoking intervention (2009) (8)
Alterations of p 14 ARF , p 53 , and p 73 Genes Involved in the E 2 F-1-mediated Apoptotic Pathways in Non-Small Cell Lung Carcinoma (2001) (8)
A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes (2005) (8)
O-68 Long term results of a phase III trial comparing once a day radiotherapy (qd RT) or twice a day radiotherapy (bid RT) in limited stage small cell lung cancer (LSCLC) (2003) (8)
Chemotherapy for advanced lung cancer. When to expect a response. (1997) (7)
Status of Journal of Thoracic Oncology in 2011 (2012) (7)
Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement (2005) (7)
Magnetic resonance imaging of the chest: a diagnostic comparison with computed tomography and hilar tomography. (1984) (7)
Erratum: Radiographic imaging of bronchioloalveolar carcinoma: Screening, patterns of presentation and response assessment (Journal of Thoracic Oncology (2006) 1, (S20-S26)) (2007) (7)
Early detection of lung cancer: Today's approach (1998) (7)
Solitary pulmonary nodule: TB or not TB (1997) (7)
Systemic treatment of advanced lung carcinoid tumors: show me the data! (2013) (7)
Lung cancer: the American view. (1989) (7)
Screening for lung cancer: Who should be screened? (2012) (7)
Phase II NCCTG Trial of Oral Topotecan and Paclitaxel With G-CSF (Filgrastim) Support in Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer (2006) (6)
Malignant pleural mesothelioma. A proposed new staging system. (1995) (6)
Topotecan and Paclitaxel in Previously Treated Patients with Relapsed Small Cell Lung Cancer: Phase II Trial of the North Central Cancer Treatment Group (2006) (6)
Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-Small Cell Lung Cancer. (2020) (6)
O-192a SWOG 0023: A randomized phase III trial of cisplatin/etoposide(PE) plus radiation therapy followed by consolidation docetaxel then maintenance therapy with gefitinib or placebo in patients with locally advanced unresectable stage III non-small cell lung cancer (NSCLC) (2005) (6)
How to optimize staging in early non-small cell lung cancer. (2002) (6)
Computed tomography screening and lung cancer outcomes. (2007) (6)
Screening for Lung Cancer. Improving Outcomes with Better Patient Selection. (2016) (6)
Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive‐stage small cell lung cancer, N0423 (2010) (5)
Age, gender, performance status and stage outperformed stage alone in predicting overall survival (OS) in patients with small cell lung cancer: A pooled analysis of 1,623 patients from the North Central Cancer Treatment Group (2007) (5)
O-73 High dose, twice-daily thoracic radiotherapy (TRT) with daily chemotherapy in limited stage small cell lung cancer (2003) (5)
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer: Results from an ECOG prospective randomized trial of postoperative adjuvant therapy (E3590, INT0015) (2000) (5)
Changing of the Guard (2013) (5)
Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines. (1987) (5)
Lung cancer screening results: easily misunderstood. (2007) (5)
Are Airflow Obstruction and Radiographic Emphysema Risk Factors for Lung Cancer (2009) (5)
37 Docetaxel and cisplatin combination in patients with non-small cell lung cancer (NSCLC): A multicenter phase il trial (1997) (5)
53 – Clinical Aspects of Lung Cancer (2016) (4)
Impaired generation of helper T cells in a patient with chronic mucocutaneous candidiasis and malignant thymoma. (1983) (4)
P2.13-013 Determination of the Detection Lead Time for Autoantibody Biomarkers in Early Stage Lung Cancer Using the UKCTOCS Cohort (2017) (4)
Computed Tomography Screening for Lung Cancer—Reply (2007) (4)
Effect of various immunoregulatory substances on the growth inhibitory activity (GIA) of human monocytes against lymphoblastoid cell lines. (1982) (4)
Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study (2008) (4)
Advances in treatment for non-small cell lung cancer. (2010) (3)
An Autoantibody Test (AABT) to Aid in Early Detection of Lung Cancer in High-Risk Patients is Likely to be Cost-Effective (2010) (3)
The value of combined modality therapy in elderly patients with stage III non-small cell lung cancer (NSCLC) (2007) (3)
Malignant Pleural Mesothelioma (1995) (3)
Gemcitabine and epirubicin in patients with malignant pleural mesothelioma (MPM): A North Central Cancer Treatment Group phase II study (2005) (3)
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (2015) (3)
Solitary pulmonary nodule: New face on an old problem (2000) (3)
Body plethysmography in the evaluation of intrathoracic airway abnormalities. (1992) (3)
7 – Screening for Lung Cancer (2018) (3)
Aryl hydrocarbon hydroxylase activity in subpopulations of peripheral blood mononuclear cells. (1978) (3)
E05-02: IASLC Staging Project: T-desriptors (2007) (3)
The colony inhibition of a new chemotherapeutic agent (KW2152) against human lung cancer cell lines (2004) (3)
A Phase II NCCTG Study of Irinotecan and Docetaxel in Previously Treated Patients with Non-Small Cell Lung Cancer (2006) (3)
Chapter 47 – Lung Tumors (2008) (3)
The Analysis of Volatile Organic Compound Profiles in the Breath as a Biomarker of Lung Cancer (2013) (3)
Screening for lung cancer: no longer a taboo subject. (2002) (3)
P1.07-016 Comparison of PD-L1 Immunohistochemical Staining between EBUS-TBNA and Resected Non-Small Cell Lung Cancer Specimens (2017) (2)
Lung cancer screening in 2008: A review and update (2008) (2)
LUNG MASS AS A MANIFESTATION OF IGG4-RELATED LUNG DISEASE (2009) (2)
PD-080 A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes (2005) (2)
Alterations of p14 ARF , p53 , and p73 Genes Involved in the E2F-1-mediated Apoptotic Pathways in Non-Small Cell Lung Carcinoma (2001) (2)
Outcome in Patients Presenting With Regional Lymph Node Involvement (2017) (2)
Pilot studies of the north central cancer treatment group (NCCTG) utilizing accelerated hyperfractionated thoracic radiation therapy (AHTRT) in unresectable stage IIIA/B non-small cell lung cancer (NSCLC) (1994) (2)
IDENTIFICATION OF LIKELY MALIGNANT INDETERMINATE PULMONARY NODULES BY ANALYSIS OF AUTOANTIBODIES AGAINST LUNG CANCER-ASSOCIATED ANTIGENS (2020) (2)
Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. (2010) (2)
Effect of a Rule-in Biomarker Test on Pulmonary Nodule Management: A Survey of Pulmonologists and Thoracic Surgeons. (2019) (2)
Development of a multivariate model to predict the likelihood of carcinoma in patients with indeterminate peripheral lung nodules after a nondiagnostic bronchoscopic evaluation. (2014) (2)
Stage II (T3) lung cancer. (2001) (2)
Pulmonary resection of metastatic colorectal adenocarcinoma. A ten year experience. 1986. (2009) (2)
Five-year Lung Cancer Screening Experience: CTAppearance,GrowthRate, Location,andHistologicFeaturesof (2007) (2)
Invasive and noninvasive advances in the staging of lung cancer. (2014) (2)
Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma of the lung. (1996) (2)
O-55 The outcome of combined modality therapy for non-small cell lung cancer (NSCLC) in the elderly (2003) (2)
Principled Lung Cancer Screening Follows Screening Principles. (2018) (2)
Cost-Effectiveness of Screening Older Adult Smokers for Lung Cancer with an Autoantibody Test (AABT) (2011) (2)
Combined modality therapy in small cell lung cancer. (1994) (2)
Screening for lung cancer with low-dose CT scans. (2013) (2)
Year Book of Pulmonary Disease (1993) (2)
MTE 27.01 Who Should be Screened for Lung Cancer (2017) (2)
A phase I/II NCCTG trial of escalating doses of twice daily thoracic radiation therapy (TRT) in limited-stage small cell lung cancer (LSCLC) (2005) (1)
(S014) Long-Terms Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance) (2017) (1)
What is the value added of patient reported outcomes relative to physician rated symptom assessments? (2006) (1)
IASLC Staging Project: T-desriptors: E05-02 (2007) (1)
P2.11-10 Potential Utility of a Positive EarlyCDT®-Lung Blood Biomarker Test in Indeterminate Pulmonary Nodules (2018) (1)
Docetaxel and irinotecan: An active non-platinum based regimen for the treatment of non-small cell lung cancer (2000) (1)
P1.03-077 Analysis of the Early CDT-Blood Biomarker for Lung Cancer in Higher vs. Lower Risk Cohorts: Topic: Staging (2017) (1)
Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer. (2012) (1)
Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. (2016) (1)
A blood test for early detection of lung cancer. (2016) (1)
The Results of combined modality therapy for limited stage small cell lung cancer (LD-SCLC) in the elderly. (2004) (1)
JTO: An Excellent First Year! (2007) (1)
The different effects of recombinant human tumor necrosis factor on rat fibrosarcoma sublines (2004) (1)
Autoantibody Test Helps Identify Malignant Pulmonary Nodules: PD.2.03 (2018) (1)
IBS11.03 Cannabis and Lung Cancer (2019) (1)
P-616 Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer (2005) (1)
A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC) (2005) (1)
Cost-effectiveness of an autoantibody test (AABT) as an aid to diagnosis of lung cancer. (2010) (1)
Paclitaxel and carboplatin with simultaneous thoracic irradiation in regionally advanced non-small cell lung cancer (1997) (1)
FLUORESCENCE IN SITU HYBRIDIZATION REFLEX ANALYSIS OF BRONCHIAL BRUSHING SPECIMENS INCREASES DETECTION OF PRIMARY LUNG CARCINOMA IN PERIPHERAL NODULES (2008) (1)
P1.03-007 Improvement in Performance of an Autoantibody Panel Test for Detection of Lung Cancer by Addition of a Single Novel Biomarker (EDB1): Topic: Biology (2017) (1)
Evaluation of platinum-based chemotherapy, glutathione metabolic genes, and survival in advanced non small cell lung cancer: A NCCTG 97-24-51 based study. (2006) (1)
P1.03-045 Screening for Lung Cancer with Early CDT-Lung Blood Biomarkers and Computed Tomography: Topic: Screening (2017) (1)
Stage-associated incidence of serum circulating immune complexes in patients with untreated bronchogenic carcinoma (1982) (1)
The Relationship Between Emphysema on CT Scan and Lung Cancer: Response (2011) (1)
Diagnostic workup of screen-detected lesions (2005) (0)
Treatment of Small Cell Lung Neoplasms by Drug Therapy (2018) (0)
P-368 Utility of FDG-PET in the evaluation of small cell lung carcinoma (2005) (0)
Comprar Clinical Respiratory Medicine - Expert Consult - Online and Print 4Ed | James R. Jett | 9781455707928 | Mosby (2012) (0)
The O utcome o f C ombined-Modalit y T herapy f or S tage I II Non-Small-Cell L ung C ancer i n t he E lderly (2003) (0)
My Take on the National Lung Screening Trial (2010) (0)
2145 Results of multi-field conformal radiation therapy of non-small cell lung cancer using multi-leaf collimator beams (1996) (0)
Living With Lung Cancer: A Guide for Patients and Their Families (1988) (0)
Extent of nodal dissection and patient age impact recurrence-free survival (RFS) after surgery for non-small cell lung cancer (NSCLC) (2007) (0)
The Results of combined modality therapy for limited stage small cell lung cancer (LD-SCLC) in the elderly (2004) (0)
ES08.04 Biomarkers in the Evaluation of Pulmonary Nodule (2021) (0)
Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium (2015) (0)
Glomus Tumor of the Trache (2003) (0)
The current management of thymic tumors (1997) (0)
PD-058 Screening for lung cancer with low-dose spiral computed tomography (SCT): 5-year results of the mayo clinic trial (2005) (0)
LUNG NODULE INTEGRATED CLASSIFIER BIOMARKER: FIRST DATA WITH REAL-WORLD CLINICAL USE (2020) (0)
P-176 A comparison of fluorescence in situ hybridization and cytologyfor detecting lung cancer in bronchoscopic specimens (2005) (0)
Should lung cancer screening with low-dose computed tomography be routine for smokers and former smokers? should low-dose CT Be routine in these patients? Most certainly! (2014) (0)
P-261 Ancillary findings noted at initial screening for lung cancer with low-dose spiral computed tomography (2003) (0)
Glutathione pathway genes predict quality of life (QOL) in lung cancer patients: A NCCTG-97-24-51 based study (2007) (0)
AProspective Study ofPulmonary Function inPatients Receiving Mitomycin (2015) (0)
The Intersection of Lung Cancer Screening, Radiomics, and Artificial Intelligence: Can One Scan Really Predict the Future Development of Lung Cancer? (2023) (0)
Oral topotecan and intravenous carboplatin with G-CSF support in previously treated patients with extensive stage small cell lung cancer: A phase II trial of the North Central Cancer Treatment Group. (2004) (0)
The Value of Bronchoscopy in the Diagnosis CHEST , 80 : 5 , NOVEMBER , 1981 BRONCHOSCOPY IN DIAGNOSIS OF MYCOBACTERIAL DISEASE 575 of Mycobacterial Disease (2006) (0)
State of the Journal: 2010 (2010) (0)
BLOOD REPOSITORY FOR THE VALIDATION OF LUNG CANCER BIOMARKERS LUNG CANCER BIOMARKERS GROUP (2007) (0)
Advances in NSCLC (2011) (0)
MTP11-01: Pulmonary toxicity of therapy (2007) (0)
Role of PET-CT in the evaluation of pleural and extrapleural mesothelioma (2007) (0)
Computed tomography screening for lung cancer. Authors' reply (2007) (0)
P-256 Screening using CT and sputum cytology detects lung cancer at an early stage (2003) (0)
Biology of Lung Cancer: Diagnosis and Treatment (Lung Biology in Health and Disease, Vol 37) (1989) (0)
O-35 Utility of FDG-PET in the diagnostic evaluation of small pulmonary nodules (2003) (0)
Old Habits Die Hard; Managing Lung Nodules with Size Slone Is Not Sufficient (0)
Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer (2015) (0)
E33. Pet scanning for evaluation of solitary pulmonary nodule and staging of NSCLC (2005) (0)
Multi-Institutio nal P hase I /II T rial o f P aclitaxel, Cisplatin, a nd E toposide W ith C oncurrent R adiation f or Limited-Stage S mall-Cell L ung C arcinoma (2000) (0)
SPIRAL CT SCREENING FOR LUNG CANCER IS READY FOR PRIME TIME (2006) (0)
USE OF TWO BLOOD-BASED BIOMARKER TESTS IN SERIES TO RECLASSIFY RISK OF INDETERMINATE PULMONARY NODULES (2020) (0)
Considerations inOptimizing Radiation Therapy for Non-small CellLung Cancer* (2017) (0)
Response to Letter to the Editor. (2020) (0)
Managing Lung Nodules Using Telemedicine and Molecular Biomarkers During the COVID-19 Pandemic (2020) (0)
Lemierre's syndrome presenting with multiple pulmonary nodules and pleural effusions (1999) (0)
The Current Status of CT Screening For Lung Cancer continued from page 2 (0)
Electronic Updates for JTO Readers (2011) (0)
ANEMIA AND AN ANTERIOR MEDIASTINAL MASS (2005) (0)
P-462 Fluorescence in situ hybridization for the detection of various lung cancer histologic subtypes from bronchial brushing specimens (2003) (0)
Variant E1038G of the BRCA1 gene is associated with lung cancer in families with multiple breast/ovarian cancer relatives (2000) (0)
Peripheral Blood Mononuclear Cells Aryl Hydrocarbon Hydroxylase Activity in Subpopulations of Updated (2006) (0)
Multi-Institutional Trial Of A Lung Cancer Risk Test (2010) (0)
Chapter 70 – Malignant Pleural Mesothelioma (2008) (0)
Screening for Lung Cancer with Low-Dose CT Scans (2014) (0)
P1-087: The role of Positron Emission Tomography (PET) in the evaluation of Paraneoplastic Neurologic Syndrome (PNS) (2007) (0)
Treatment of non-small-cell lung cancer. (1996) (0)
Value of a serum proteomic signature in the non-invasive evaluation of lung nodules. (2010) (0)
Clinical Presentation and Diagnosis of Tracheal Neoplasms (2018) (0)
E-42. Screening and early detection of lung cancer (2003) (0)
Phase I II C omparison o f T wice-Daily S plit-Course Irradiation V ersus O nce-Daily I rradiation f or P atients With L imited S tage S mall-Cell L ung C arcinoma (1999) (0)
State of the Journal. (2008) (0)
899 The role of positron emission tomography (PET) scan in staging non-small cell lung cancer (1997) (0)
Impact of the algorithm for declaring exact progression date on progression-free survival (PFS) estimates in advanced lung cancer clinical trials. (2010) (0)
Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation (2008) (0)
Utility of Positron Emission Tomography in Evaluation of Carcinoid Tumors Presenting as Solitary Pulmonary Nodule (2003) (0)
O-068 Sensitivity of FDG-PET in the diagnostic evaluation of small pulmonary nodules (2005) (0)
KNOWLEDGE AND PRACTICE PATTERNS AMONG PULMONOLOGISTS FOR MOLECULAR BIOMARKER TESTING IN ADVANCED NON-SMALL CELL LUNG CANCER (2020) (0)
8:00-8:25 Presentation, Diagnosis, and Evaluation of Lung Cancer by Pulmonary Physicians (2000) (0)
Lung cancer in the elderly (1993) (0)
The role of glutathione-related genes in lung cancer survival (1999) (0)
P-539 Lung cancer with malignant pleural effusion: Clinical and survival characteristics (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With James R. Jett?

James R. Jett is affiliated with the following schools:

University of Kentucky
University of Washington
University of Alabama at Birmingham

James R. Jett's Academic­Influence.com Rankings

Why Is James R. Jett Influential?

James R. Jett's Published Works

Published Works

What Schools Are Affiliated With James R. Jett?

James R. Jett's AcademicInfluence.com Rankings